Home > Publications Database > Is CAA a perivascular brain clearance disease? A discussion of the evidence to date and outlook for future studies. > print

001     269784
005     20240808164353.0
024 7 _ |a pmc:PMC11130115
|2 pmc
024 7 _ |a 10.1007/s00018-024-05277-1
|2 doi
024 7 _ |a pmid:38801464
|2 pmid
024 7 _ |a 1420-682X
|2 ISSN
024 7 _ |a 0014-4754
|2 ISSN
024 7 _ |a 1420-9071
|2 ISSN
024 7 _ |a altmetric:163994205
|2 altmetric
037 _ _ |a DZNE-2024-00619
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a van Veluw, Susanne J
|0 0000-0002-7957-8643
|b 0
245 _ _ |a Is CAA a perivascular brain clearance disease? A discussion of the evidence to date and outlook for future studies.
260 _ _ |a Cham (ZG)
|c 2024
|b Springer International Publishing AG
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1716898045_18043
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The brain's network of perivascular channels for clearance of excess fluids and waste plays a critical role in the pathogenesis of several neurodegenerative diseases including cerebral amyloid angiopathy (CAA). CAA is the main cause of hemorrhagic stroke in the elderly, the most common vascular comorbidity in Alzheimer's disease and also implicated in adverse events related to anti-amyloid immunotherapy. Remarkably, the mechanisms governing perivascular clearance of soluble amyloid β-a key culprit in CAA-from the brain to draining lymphatics and systemic circulation remains poorly understood. This knowledge gap is critically important to bridge for understanding the pathophysiology of CAA and accelerate development of targeted therapeutics. The authors of this review recently converged their diverse expertise in the field of perivascular physiology to specifically address this problem within the framework of a Leducq Foundation Transatlantic Network of Excellence on Brain Clearance. This review discusses the overarching goal of the consortium and explores the evidence supporting or refuting the role of impaired perivascular clearance in the pathophysiology of CAA with a focus on translating observations from rodents to humans. We also discuss the anatomical features of perivascular channels as well as the biophysical characteristics of fluid and solute transport.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Brain clearance
|2 Other
650 _ 7 |a Cerebral amyloid angiopathy
|2 Other
650 _ 7 |a Cerebrospinal fluid
|2 Other
650 _ 7 |a Glymphatics
|2 Other
650 _ 7 |a IPAD
|2 Other
650 _ 7 |a Perivascular spaces
|2 Other
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Cerebral Amyloid Angiopathy: metabolism
|2 MeSH
650 _ 2 |a Cerebral Amyloid Angiopathy: pathology
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Glymphatic System: metabolism
|2 MeSH
650 _ 2 |a Glymphatic System: pathology
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
700 1 _ |a Benveniste, Helene
|b 1
700 1 _ |a Bakker, Erik N T P
|b 2
700 1 _ |a Carare, Roxana O
|b 3
700 1 _ |a Greenberg, Steven M
|b 4
700 1 _ |a Iliff, Jeffrey J
|b 5
700 1 _ |a Lorthois, Sylvie
|b 6
700 1 _ |a Van Nostrand, William E
|b 7
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 8
|u dzne
700 1 _ |a Shih, Andy Y
|b 9
700 1 _ |a van Osch, Matthias J P
|b 10
773 _ _ |a 10.1007/s00018-024-05277-1
|g Vol. 81, no. 1, p. 239
|0 PERI:(DE-600)1458497-9
|n 1
|p 239
|t Cellular and molecular life sciences
|v 81
|y 2024
|x 1420-682X
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/269784/files/DZNE-2024-00619.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/269784/files/DZNE-2024-00619.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:269784
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810273
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold ; AG Petzold
|l Vascular Neurology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013020
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21